Avalo Therapeutics, Inc. (AVTX)
NASDAQ: AVTX · Real-Time Price · USD
17.67
+0.09 (0.48%)
Mar 6, 2026, 2:23 PM EST - Market open
Avalo Therapeutics Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for Avalo Therapeutics stock have an average target of 32.57, with a low estimate of 15 and a high estimate of 50. The average target predicts an increase of 84.38% from the current stock price of 17.67.
Analyst Consensus: Strong Buy
* Price targets were last updated on Feb 2, 2026.
Analyst Ratings
The average analyst rating for Avalo Therapeutics stock from 9 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 5 | 5 | 6 | 6 |
| Buy | 2 | 2 | 3 | 3 | 3 | 2 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 9 | 9 | 10 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Guggenheim | Guggenheim | Strong Buy Initiates $50 | Strong Buy | Initiates | $50 | +183.05% | Feb 2, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $25 | Strong Buy | Reiterates | $25 | +41.52% | Jan 15, 2026 |
| Mizuho | Mizuho | Buy Initiates $39 | Buy | Initiates | $39 | +120.78% | Dec 18, 2025 |
| BTIG | BTIG | Strong Buy Reiterates $40 | Strong Buy | Reiterates | $40 | +126.44% | Sep 29, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $15 → $25 | Strong Buy | Maintains | $15 → $25 | +41.52% | Sep 17, 2025 |
Financial Forecast
Revenue This Year
n/a
from 441.00K
Revenue Next Year
n/a
EPS This Year
-6.20
from -20.91
EPS Next Year
-5.17
from -6.20
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | n/a | n/a | ||||
| Avg | n/a | n/a | ||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -1.47 | -1.94 | ||||
| Avg | -6.20 | -5.17 | ||||
| Low | -7.28 | -7.53 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.